fluorouracil has been researched along with rucaparib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bertolini, F; Debatin, KM; Di Rorà, AG; Falzacappa, MV; Faretta, M; Iacobucci, I; Martinelli, G; Meyer, LH; Orecchioni, S; Pelicci, PG; Ronchini, C | 1 |
2 other study(ies) available for fluorouracil and rucaparib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA Damage; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Indoles; Leukemia; Male; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays | 2015 |